Transition Bio is developing one-of-a-kind technologies for biomolecular condensate analysis. Through our Condensomics platform, our goal is to build a drug discovery engine based on the latest advancements in biophysics and artificial intelligence. We harness droplet microfluidic approaches and cellular platforms to characterize condensates with unprecedented scale and precision, resulting in the mapping of condensates and their modulation, in molecular detail. Our proprietary datasets feed in to algorithms that we use for target discovery, target validation and drug design.
Company Details
- Employees
- 26
- Address
- Cambridge, Massachusetts, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.transitionbio.com
- Keywords
- Manager jobs.
- HQ
- Cambridge, Massachusetts
Transition Bio, Inc. Questions
Transition Bio, Inc.'s website is http://www.transitionbio.com
Transition Bio, Inc.'s LinkedIn profile is https://www.linkedin.com/company/transition-bio-inc
Transition Bio, Inc. has
26 employees.
View email and phone details for 26
employees at Transition Bio, Inc..
Transition Bio, Inc.'s industry is
Biotechnology Research
Transition Bio, Inc.'s top competitors are
Nona Biosciences,
Climb Bio,
Kytopen,
Marengo Therapeutics,
Phast,
Incendia Therapeutics,
Pledge Therapeutics,
1910 Genetics,
Qld Biotherapeutics Inc,
Vivtex.
Transition Bio, Inc.'s categories are Biotechnology Research
